All anabolic steroids exhibit negative cholesterol profile changes in the body to varying extent (some exhibit this more and some less). These changes involve the reduction of HDL (the good cholesterol) and increases of LDL (the bad cholesterol). The result of such changes involves an increased risk of arteriosclerosis, and the degree to which these changes occur for the worse are usually dose-dependent (with higher doses increasing the negative changes and the risks). Other factors that affect these negative cholesterol changes are: duration of use, and route of administration. This is where oral anabolic steroids hold a negative reputation for exhibiting a far worse negative impact on cholesterol in comparison to injectable anabolic steroids. This is because the liver serves to function as the cholesterol processing center for the human body, and the increased hepatotoxicity associated with anabolic steroids will result in even worse negative cholesterol changes.
When first administering steroids, a man will have an increase in sexual function. This unfortunately is only temporary as your body becomes used to the steroid in its system. With prolonged use of a steroid, eventually, the man will feel less sexual desire, and will be less capable of maintaining an erection. Luckily, this is only temporary as well and can even be totally prevented with the use of substance such as Gonakor and HCG. Also when the steroid use is discontinued, the body’s natural level of testosterone (like the immune system) will certainly be suppressed.
American Medical Association, Council on Scientific Affairs. Medical and non-medical uses of anabolic-androgenic steroids. J. Amer. Med. Assoc. 264: 2923-2927, 1990.
Bahrke, ., . Yesalosk, and . Wright. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review. Sports Med. 10: 303-337, 1990.
Buckley, ., . Yasalis, . Friedl, . Anderson, . Streit, and . Wright. Estimated prevalance of anabolic steroid use among male high school seniors. J. Amer. Med. Assoc. 260: 3441-3445, 1988.
Rogozkin, V. Metabolism of Anabolic Androgenic Steroids. Leningrad: Nauka, 1988.
United States Olympic Committee. USOC Drug Education Handbook. Colorado Springs: USOC, 1989.
Assessment of Aggressive Behavior and Plasma Testosterone in a Young Criminal PopulationLeo E. Kreuz, MD, MAJ, MCand Robert M. Rose, MD, June 23, 1971. Revision received December 1, 1971. 1972 American Psychosomatic Society
BEHRE, ., K. ABSHAGEN, M. OETTEL, D. HUBLER AND E. NIESCHLAG. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414 ***8211; 419. 1999